Prior Bexarotene or Phototherapy Does Not Affect Response to Chlormethine Gel: Post Hoc Analysis of a Pivotal Trial


  • Chalid Assaf Department of Dermatology and Venereology, Helios Klinikum Krefeld, Krefeld, Germany; Institute for Molecular Medicine, Medical School Hamburg, Hamburg, Germany
  • Christiane Querfeld City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA, USA
  • Marta Scandurra Helsinn Healthcare SA, Lugano, Switzerland
  • Marco Turini Helsinn Healthcare SA, Lugano, Switzerland
  • Julia J. Scarisbrick University of Birmingham, Birmingham, UK



mycosis fungoides, chlormethine gel, response rates, prior treatment, posthoc analysis


Abstract is missing (Short communication)


Download data is not yet available.


Valchlor (mechlorethamine gel) [prescribing information]. Iselin, NJ: Helsinn Therapeutics (U.S.), Inc. [Accessed 28 September 2022]. Available from:

Lessin SR, Duvic M, Guitart J, Pandya AG, Strober BE, Olsen EA, et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol 2013; 149: 25-32. DOI:

Querfeld C, Scarisbrick JJ, Assaf C, Guenova E, Bagot M, Ortiz-Romero PL, et al. Post hoc analysis of a randomized, controlled, phase 2 study to assess response rates with chlormethine/mechlorethamine gel in patients with stage IA-IIA mycosis fungoides. Dermatology 2022; 238: 347-357. DOI:

Willemze R, Hodak E, Zinzani PL, Specht L, Ladetto M, ESMO Guidelines Committee. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29: iv30-40. DOI:

Trautinger F, Eder J, Assaf C, Bagot M, Cozzio A, Dummer R, et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - update 2017. Eur J Cancer 2017; 77: 57-74. DOI:

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Primary cutaneous lymphoma. Version 2.2022. 2022. [Accessed 28 September 2022]. Available from:

Wehkamp U, Jost M, Gosmann J, Grote U, Bernard M, Stadler R. Management of chlormethine gel treatment in mycosis fungoides patients in two German skin lymphoma centers. J Dtsch Dermatol Ges 2021; 19: 1057-1059. DOI:

Papadavid E, Koumourtzis M, Nikolaou V, Lampadaki K, Marinos L, Patsatsi A, et al. Chlormethine gel is effective for the treatment of skin lesions in patients with early- and late-stage mycosis fungoides in clinical practice. J Eur Acad Dermatol Venereol 2022; 36: 1751-1757. DOI:

Kim EJ, Guitart J, Querfeld C, Girardi M, Musiek A, Akilov OE, et al. The PROVe study: US real-world experience with chlormethine/mechlorethamine gel in combination with other therapies for patients with mycosis fungoides cutaneous T-cell lymphoma. Am J Clin Dermatol 2021; 22: 407-414. DOI:

Assaf C, Booken N, Dippel E, Guenova E, Jonak C, Klemke CD, et al. The optimal use of chlormethine gel for mycosis fungoides: an expert consensus from Germany, Austria and Switzerland (DACH region). J Dtsch Dermatol Ges 2022; 20: 579-586. DOI:



How to Cite

Assaf, C., Querfeld, C., Scandurra, M., Turini, M., & Scarisbrick, J. J. . (2023). Prior Bexarotene or Phototherapy Does Not Affect Response to Chlormethine Gel: Post Hoc Analysis of a Pivotal Trial. Acta Dermato-Venereologica, 103, adv00862.



Short Communication